Novimmune SA Sustainability Profile
Novimmune SA, headquartered in Switzerland (CH), is a pioneering biotechnology company specialising in the development of innovative therapeutic antibodies. Founded in 2007, Novimmune has made significant strides in the biopharmaceutical industry, focusing on areas such as oncology and autoimmune diseases. The company is renowned for its proprietary antibody discovery platform, which enables the creation of unique, high-affinity antibodies tailored to target specific disease mechanisms. Novimmune's commitment to advancing healthcare is reflected in its robust pipeline of clinical candidates, positioning it as a key player in the global biotechnology landscape. With a strong emphasis on research and development, Novimmune continues to achieve notable milestones, contributing to the evolution of targeted therapies and improving patient outcomes worldwide.
DitchCarbon Score
How does Novimmune SA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novimmune SA's score of 26 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novimmune SA's reported carbon emissions
Novimmune SA, headquartered in Switzerland (CH), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary and does not inherit emissions data from a parent organization. In terms of climate commitments, Novimmune SA has not outlined any specific reduction targets or initiatives, nor does it participate in recognised frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). This lack of publicly available data suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. As the industry increasingly prioritises sustainability, Novimmune SA's future climate commitments and potential emissions reporting will be crucial for aligning with global climate goals and enhancing its environmental accountability.
How Carbon Intensive is Novimmune SA's Industry?
How Carbon Intensive is Novimmune SA's Location?
Novimmune SA's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novimmune SA has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
